Search
Background: High incidence and serotype diversity of invasive pneumococcal disease (IPD) in Indigenous children in remote Australia led to rapid introduction of
Influenza is major cause of paediatric hospitalisation. Influenza vaccine was offered to all children aged 6-59 months resident in Western Australia in 2008
Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.
Australian Aboriginal people have among the highest rates of invasive pneumococcal disease (IPD) worldwide. This paper investigates clinical diagnosis, risk...
Children with birth defects experience higher rates of hospitalisation for ALRIs before age 2 years than children with no birth defects.
The transmission dynamics of RSV infection among young children are still poorly understood and mathematical modelling can be used to better understand...
Human rhinovirus (HRV) species C (HRV-C) have been associated with frequent and severe acute lower respiratory infections and asthma in hospitalized children.
In the 1990s pneumonia hospitalisation rates in Western Australia (WA) were 13 times higher in Indigenous children than in non-Indigenous children...
In 2024, the government of Western Australia introduced 'nirsevimab', a monoclonal antibody offering protection from respiratory syncytial virus (RSV), for eligible infants. This study explores why parents of infants who were eligible to receive nirsevimab opted to decline or delay the immunisation.
The COVID-19 pandemic drove the implementation of vaccine mandates to protect spaces and/or increase vaccine uptake, though their design, timing, and scope varied across jurisdictions. This study examines the associations of vaccine mandate announcements and removals with COVID-19 vaccine uptake in France, Italy, and California (USA).